Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.11 EUR
Change Today +0.021 / 1.00%
Volume 200.0
B8F On Other Exchanges
As of 4:15 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/3/14 - €3.25
52 Week Low
02/26/15 - €1.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; and Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

49 Employees
Last Reported Date: 05/29/15
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €405.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €202.0K
Compensation as of Fiscal Year 2014.

biofrontera ag (B8F) Key Developments

Biofrontera AG Appoints Christoph Dünwald as Chief Commercial Officer

Biofrontera AG announced the appointment of Christoph Dünwald as Chief Commercial Officer. Mr. Dunwald will lead the sales and marketing of the Group as a member of the management board, which he is envisaged to join with effect from November 16, 2015, due to an existing non-compete clause. Mr. Dünwald brings 24 years of comprehensive sales and marketing expertise in the healthcare sector which he gained working for pharmaceutical businesses in Europe, Asia Pacific and the US.

Biofrontera AG Launches Skincare Product

Biofrontera launching another product in its Belixos® dermo-cosmetic line. Belixos® Protect, a regenerative daily skin care product for sun-damaged skin, complements the Belixos® dermo-cosmetic line and bridges the gap between Biofrontera's medicinal product Ameluz® for the treatment of sun-induced skin cancer and the Belixos® line. Combining skin regenerating niacinamide with sun protection factor 15, Belixos® Protect was developed specifically for the needs of sun-damaged skin and provides ideal daily care for skin that already shows signs of damage by UV light. UV light damages the genetic material of skin cells and may eventually transform them into cancer cells. Skin cells can repair damage caused by UV light but for this, they require a large amount of energy. The highly concentrated niacinamide in Belixos® Protect provides skin cells with additional energy for these repair procedures. Thereby, Belixos® Protect helps the skin to regenerate itself and to reduce existing signs of skin ageing. Scientific studies have demonstrated that niacinamide reduces the fine lines that are perceived as withered skin. In addition, the cream contains a nurturing lipid matrix consisting of biocolloids, ceramides, and shea butter. It is pleasant to apply, absorbed rapidly and is also ideal for sensitive skin types. An active ingredient complex of vitamin B3 and vitamin E smoothes the skin, protects against moisture loss and reduces pore size and hyperpigmentation. The carefully chosen sun protection factor 15 is adequate for most daily sun exposure scenarios and therefore avoids unnecessarily high dosing of UV filters. Belixos® Protect is the fourth product in Biofrontera's medical skincare line and complements Belixos® cream, Belixos® liquid hair tonic, and Belixos® gel that meet the special needs of reddened and itchy skin on different skin types of the body, whereas Belixos® Protect was prepared for everybody aware of the dangers of UV irradiation who cast about a daily protective and nurturing skin care. The new product is available in a pump dispenser containing 50 ml.

Biofrontera AG Submits New Drug Application for Ameluz to FDA

Biofrontera AG announced that it has completed a major milestone by submitting a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its combination prescription drug Ameluz and medical device BF-RhodoLED. The combination of both products shall be applied in photodynamic therapy in the USA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.11 EUR +0.021

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies

Industry Analysis


Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at